What is Incyte's NIKTIMVO — total revenues?

Incyte (INCY) reported NIKTIMVO — total revenues of $55.09M in Q1 2026.

How has Incyte's NIKTIMVO — total revenues changed year-over-year?

Incyte's NIKTIMVO — total revenues increased by 304.7% year-over-year, from $13.61M to $55.09M.

What does NIKTIMVO — total revenues mean?

This metric represents the total gross revenue generated from the sale and commercialization of the specific pharmaceutical product NIKTIMVO. It reflects the market adoption, pricing power, and clinical demand for this therapeutic asset within the company's oncology portfolio. Tracking this revenue stream is essential for evaluating the commercial success of new product launches and their contribution to the firm's overall top-line growth.

Incyte INCY NIKTIMVO — Total revenues

Other product segments

JAKAFI

$757.76M+6.8%

OPZELURA

$143.02M+20.5%

JAKAVI Royalty Revenues

$105.56M+14.6%

MINJUVI/MONJUVI

$49.23M+66.6%

ZYNYZ

$41.39M+1,276%

OLUMIANT Royalty Revenues

$36.41M+18.2%

ICLUSIG

$35.46M+20.0%

PEMAZYRE

$22.54M+22.3%

Milestone and contract revenues

$17M—

TABRECTA Royalty Revenues

$5.98M-6.7%

Other product royalty revenues

$3.25M+156%

Similar metrics at other companies

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

SDGROncology, Neurology, and Immunology Product — Total revenues

$700K+16.7%

PTH

PTHSNet product revenues — Total Revenue

$10.67M—

ESP

ESPRProduct sales, net — Total Revenues

$43.4M+24.3%

TVTXTotal net product sales — Total Revenue

$124.49M+64.1%

NVAXNuvaxovid sales — Total Revenue

$9.56M-98.4%

Other financials

Income statement

See full

Revenue$1.3B+20.9%

Gross profit$1.2B+19.2%

Operating income$301.1M+46.8%

Net income$303.3M+91.7%

EPS (diluted)$1.47+83.7%

Balance sheet

See full

Cash & equivalents$3.5B+78.2%

Total debt$39.4M-8.6%

Total equity$5.6B+53.3%

Total assets$7.3B+27.7%

Cash flow

See full

Operating cash flow$369.4M+38.8%

CapEx$1.6M-43.5%

Free cash flow$367.7M+39.7%

Valuation

See full

Market cap$23.32B+74.2%

Enterprise value$19.89B+73.4%

P/E16.3×+0.9×

P/S4.4×+1.4×

Profitability

See full

Gross margin92.5%-0.2pp

Operating margin30%+26.1pp

Net margin26.7%+26.2pp

FCF margin28.2%+19.7pp

Returns & leverage

See full

Return on equity30.8%+30.4pp

Debt / equity0×0.0×

Current ratio3.7×+1.6×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's niktimvo — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Incyte's NIKTIMVO — total revenues?: Incyte (INCY) reported NIKTIMVO — total revenues of $55.09M in Q1 2026.
How has Incyte's NIKTIMVO — total revenues changed year-over-year?: Incyte's NIKTIMVO — total revenues increased by 304.7% year-over-year, from $13.61M to $55.09M.
What does NIKTIMVO — total revenues mean?: This metric represents the total gross revenue generated from the sale and commercialization of the specific pharmaceutical product NIKTIMVO. It reflects the market adoption, pricing power, and clinical demand for this therapeutic asset within the company's oncology portfolio. Tracking this revenue stream is essential for evaluating the commercial success of new product launches and their contribution to the firm's overall top-line growth.